Poor
Partially Aligned
Patient Risk:
Medium
Summary
Some claims loosely match label concepts (indications include reduced MI/stroke risk; adverse reaction lists include diarrhea/nausea/dizziness and myalgia), but several statements are not supported by the provided label excerpts (e.g., mechanism described as reduced hepatic LDL production; “common side effects” for specific symptoms beyond listed most common/most reported; yoga-related impact; “not typically contraindicated”); multiple clinically relevant safety specifics are not addressed (e.g., liver testing, muscle contraindications/withhold guidance).
Category Scores
Accurate Statements
Lipitor reduces the risk of heart disease.
Section 1.1 Prevention of Cardiovascular Disease lists reduced risk of myocardial infarction and other coronary heart disease outcomes; Section 14.1 also describes reduced coronary events/revascularization/MCVE.
Lipitor reduces the risk of stroke.
Section 1.1 lists reduced risk of stroke (adult patients with multiple risk factors and those with CHD).
Unsupported Statements
Lipitor (atorvastatin) is a statin medication that reduces the production of LDL cholesterol in the liver.
The provided label excerpts do not state “reduces the production of LDL cholesterol in the liver.”
By lowering LDL cholesterol, Lipitor helps prevent the buildup of plaque in the arteries.
While Section 12.1 mentions cholesterol/triglycerides and LDL promote atherosclerosis, the provided excerpts do not explicitly support the specific causal phrasing “prevents the buildup of plaque in the arteries.”
Common side effects of Lipitor include muscle pain or weakness.
Section 6.1 lists myalgia as a common adverse reaction leading to discontinuation, but it does not support “muscle pain or weakness” as a broad “common side effect” category; also “weakness” is not explicitly listed in the provided excerpts.
Common side effects of Lipitor include headache.
“Headache” is not listed in the provided label excerpts under the most common adverse reactions or postmarketing experience.
Common side effects of Lipitor include dizziness.
“Dizziness” appears in postmarketing experience, but the excerpts do not support categorizing it as a “common side effect.”
Common side effects of Lipitor include nausea or vomiting.
Nausea is listed among the five most common adverse reactions leading to discontinuation, but “vomiting” is not explicitly listed; the excerpts do not support “nausea or vomiting” as a combined common side effect.
Common side effects of Lipitor include diarrhea.
Diarrhea is listed (both among five most common leading to discontinuation and as most commonly reported ≥2%); however the claim’s broad “common side effects” framing is only partially supported because it is not limited to the specific trial-based categories shown.
Common side effects of Lipitor include abdominal pain.
“Abdominal pain” is not listed in the provided label excerpts.
Lipitor can cause muscle pain or weakness that may make it more challenging to perform certain yoga poses requiring strength or flexibility.
Yoga-specific functional impacts are not addressed in the provided label excerpts.
Lipitor can cause dizziness or lightheadedness that may increase the risk of falls or injuries during yoga practice.
Falls/injury risk or yoga-practice context is not addressed in the provided label excerpts (and “lightheadedness” is not explicitly listed).
Lipitor can cause nausea or vomiting that may make it difficult to maintain a balanced diet and stay hydrated during yoga practice.
The provided label excerpts do not address hydration/diet effects in the context of yoga practice.
Lipitor is not typically contraindicated with yoga.
Contraindications are medication- and patient-condition based in the label excerpts (e.g., active liver disease, hypersensitivity, pregnancy, nursing). The provided label does not mention yoga; therefore the claim is unsupported.
Contradictions
Low
AI Statement
Do not stop taking Lipitor without consulting a healthcare professional.
Label Reference
Not directly supported or contradicted by the provided label excerpts; no label text in the excerpts instructs “do not stop” (or provides such directive).
Important Omissions
Key contraindications (e.g., active liver disease, pregnancy/fetal harm, hypersensitivity, nursing mothers) are not mentioned in the AI claims list.
Importance:
Moderate
Key safety precautions/monitoring guidance (e.g., liver function tests prior to and 12 weeks after initiation; guidance about withholding/discontinuing for acute serious myopathy conditions; higher hemorrhagic stroke incidence with LIPITOR 80 mg in patients with recent stroke/TIA) are not mentioned.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Medium
Yoga-context claims are unsupported and may distract from on-label contraindications and monitoring. Several adverse reaction claims include unsupported items (e.g., headache, abdominal pain) and imprecise “common” categorization for dizziness/vomiting/weakness; contraindications and monitoring are omitted.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Multiple claims are either not supported by the provided label excerpts (mechanism phrasing; headache/abdominal pain; yoga-related functional/fall/diet narratives) or inaccurately framed (broad “common side effects” vs label-listed trial-based most common reactions). Contradictions/omissions around contraindications and monitoring contribute to poor overall alignment.
Suggested Improvement
Restrict statements to what the provided label excerpts support (e.g., explicitly listed indications outcomes; adverse reactions from Sections 6.1/6.2; avoid unsupported yoga-specific implications; avoid “not contraindicated” phrasing; include on-label contraindications and key monitoring/withhold precautions as applicable).